Background: Most pancreatic cancer patients have disease recurrence/progression within 6 months from firstline chemotherapy end. Today, there is no a standard of care of second-line therapy.
Introduction
Pancreatic cancer is the fourth leading cause of cancer death in men and women [1] , the fifth in Europe [2] . Surgery is the only potential curative therapy and radically resection represents an important prognostic factor with an overall survival advantage in negative surgical margins patients. Unfortunately, only 10-20% of cases meeting criteria for localized and resectable disease (stage I or II) following diagnosis, while 30-40% of patients have a locally advanced or borderline resectable disease [3] and are candidates in medical treatment, due to high risks of occult metastasis and positive surgical margin in case of surgery. The 50-60% of pancreatic cancer is already metastatic at diagnosis, thus medical therapy remains the only alternative that can prolong survival, which, however, does not exceed 11 months in the most active regimens (FOLFIRINOX) [4] . Poor prognosis is mainly due to biological cancer aggressiveness and the low sensitivity to medical treatments, as systemic chemotherapy and radiotherapy. Previously studies showed pancreatic cancer sensitive to locoregional chemotherapy, due to increasing drug delivery [5] [6] [7] [8] [9] and consequent therapeutic efficacy strengthening in adjuvant and metastatic setting [10] [11] [12] [13] [14] .
Although recent advances have improved outcomes in first line therapy, the vast majority of patients have disease recurrence or progression within 6 months, as concern the most active regimens FOLFIRINOX and nab-paclitaxel gemcitabine association [4, 15] . Today, there is no a standard of care in this setting and, unfortunately, treatment options in subsequent lines are limited, partly because patient clinical condition are deteriorated and chemotherapy is often burdened by significant side effects.
Relying on these premises and on the results of previously studies, which demonstrated efficacy and safety of intra-arterial chemotherapy, we retrospectively investigated the role of gemcitabine/ capecitabine plus intra-arterial epirubicin-cisplatin (EC-GEMCAP) after FOLFIRINOX first line chemotherapy.
Patients and Methods
Patients diagnosed with histologically or citologically surgical unresectable, locally advanced or metastatic pancreatic adenocarcinoma treated with FOLFIRINOX first line chemotherapy, from January 2011 to May 2014 where eligible for analysis.
They had to have age 18 to 75 years, ECOG performance status ≤2 and adequate organ function (leukocyte count >3500/μL, haemoglobin ≥10.0 g/dL, serum creatinine <1.25 times upper limit of normal (ULN), transaminases and alkaline phosphatase <2.5 times ULN, bilirubin <1.5 times ULN).
Staging included abdominal sonography, total abdomen and chest CT scan. Weight, performance status, CA 19-9 levels, and side effects were evaluated at study entry and after each cycle of regional therapy. An abdomen and chest CT scan was repeated every 3 treatment cycles. All patients gave their informed consent according to our institutional guidelines.
Treatment plan
On day 1, epirubicin 35 mg/mq and cisplatin 42 mg/mq were administered into celiac axis by bolus injection through a catether inserted in the femoral artery with the Seldinger method.
Capecitabine was given orally at the fixed dose of 650 mg/mq twice a day, on days 2-15.
Gemcitabine was administered on day 2 of each cycle at a starting dose of 1,000 mg/mq (intravenously, over 30 minutes). Treatment was repeated every 28 days, until evidence of progression disease or in event of unacceptable toxicity, or in case of patient request.
In addition, an antiemetic (granisetron 8 mg) and an H2-receptor antagonist (famotidine 40 mg) were given intravenously.
Adverse events were recorded according to the National Cancer Institute of Canada common toxicity criteria (NCIC-CTC). The epirubicin and/or cisplatin and/or capecitabine dosage was adjusted, delayed or omitted for toxic effects ≥ grade 2, based on protocol guidelines.
The response was evaluated after 3 cycles using abdomen and chest CT scan according to Response Evaluation Criteria in Solid Tumors (RECIST), 1.1 version. In cases of clinical response, independent of CT scan response, further 3 cycles were administered.
Statistics
Demographic and clinical characteristics were retrospectively recorded in database and summarized by medians and frequencies, as appropriate.
The primary end-point was PFS, defined as the time interval between EC-GEMCAP beginning and time of disease progression based on imaging studies or death, whichever occurred first. OS was defined as the time interval between EC-GEMCAP beginning and time of death or last follow-up.
PFS and OS were estimated by Kaplan-Meier method.
A clinical response was defined as an improvement in symptoms present at the beginning of treatment and was based on the investigators' evaluation. The objective response rate was calculated as the sum of complete and partial responses. The disease control rate was defined as the sum of complete and partial responses and stable disease.
SPSS for Windows version 13 was used for data analysis.
Results
From January 2011 to May 2014, we identified 41 patients with locally advanced or metastatic pancreatic cancer treated with FOLFIRINOX first line chemotherapy. A total of 80 cycles of FOLFIRINOX was administered, a median of 8 cycles for each patient (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Ten patients also received loco-regional treatment: surgery, radiotherapy alone, radiotherapy associated to gemcitabine and termablation in 2, 2, 4 and 2 patients, respectively. Twenty seven patients (65.9%) progressed during or after first line treatment, with a median PFS of 5.2 months (range 1.6-15 months), while 14 patients (34.1%) had a stable disease.
At the beginning of second line treatment, 13 patients presented a stage III and 28 a stage IV disease. Median age was 56 years (range 42-71) and ECOG PS was 0/1/2 in 26, 8 and 7 patients (Table 1) .
We administered a total of 181 cycles of EC-GEMCAP therapy, median per patients: 3 cycles (range 1-15). Globally, treatment was well tolerated, without dose reductions or delays. All grade hematologic and no-hematologic toxicities were 65.8% and 34.1%, grade 3-4 were 39% (leucocytopenia 24.4%, thrombocytopenia 14.6%) and 12.2% (fatigue 2.4%, vomiting 7.3%, diarrhoea 2.4%), respectively ( Table 2) .
RECIST assessment was possible in 35 of 41 patients (6 patients progressed during the first 2 cycles): 20 patients (57.1%) obtained disease stability and 2 patients (5.7%) a partial response, with a disease control rate in 22 patients (62.3%). Twelve patients (37.1%) had a progression disease (Table 3) .
One patient with locally advanced disease underwent to radically surgery after 6 cycles of ECGEMCAP therapy. CA 19.9 response was evaluable for 33 patients: it was reduced in 11 (33.3%) patients (of these, normalized in 1 (3%)), stable in 9 patients (27.3%) and increased in 13 (39.4%).
After a median follow-up of 16.9 months (range 4.2-56.9 months) since diagnosis, median OS was 16.9 months (95% CI: 14.7-19.0) with a OS rates at 6, 12 and 24 months of 95.1%, 80.5% and 31.7%, respectively ( Figure 1 ).
As regards second line therapy, after median follow-up of 8.9 months (range 0.6-48.5 months) median OS was 8.9 months (95% CI: 6.9-10.9) (Figure 2 ). The OS rates at 6, 12 and 24 months were 61%, 80.5% and 31.7%, respectively. EC-GEMCAP median PFS was 4.1 months (95% CI: 3.1-5.1) (Figure 2 ). The PFS rates at 6 and 12 months were, respectively, 41.5% and 19.5%.
Discussion
Although many improvements have been made in the treatment of locally advanced pancreatic cancer, median overall survival reaches only 11.1 months for FOLFIRINOX and 8.5 months for nab-paclitaxel and gemcitabine [4, 15] , with recurrence or progression disease within 6 months from chemotherapy end. Since many patients are still fit, a second line treatment might be a reasonable choice after first line chemotherapy progression. Of course, a second line should take into account not only the previous treatments, but even patient physical condition, residual toxicity and potential side effects of other regimens.
Today, there is no consensus second line chemotherapy regimen [16] . Many phase 2 or 3 second line chemotherapy trials tested several drugs, such as gemcitabine, 5-fluorouracile, oxaliplatin, cisplatin, taxoter, irinotecan, liposomal irinotecan, nab-paclitaxel, alone or in combination, after a based gemcitabine (alone or in combination) or 5-flourouralice plus cisplatin first line chemotherapy, showing a median PFS of 2.3 months (range 1.5-5.1) and a median OS of 4.82 months (range 3.3-9.9) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Regarding second line chemotherapy after FOLFIRINOX, in the Conroy et al. study 80 patients received gemcitabine (82.5%) or a gemcitabine based chemotherapy (12.5%), while 85 patients in gemcitabine first line chemotherapy group received a second line with FOLFOX (49.4%), or gemcitabine plus cisplatin (17.6%), or a regimen of fluorouracil and leucovorin plus cicplatin (16.5%), or FOLFIRINOX (4.7%) [4] . Interesting, no difference in median OS was noted between the groups (4.4 month in each arm) from the introduction of second line therapy.
Most recently, Portal et al. reported results on 57 patients prospectively treated with nabpaclitaxel and gemcitabine after FOLFIRINOX failure [27] . During the recruitment period, 110 patients stopped FOLFIRINOX for progression or toxicity, and 77 (70%) of them were eligible to receive nab-paclitaxel plus gemcitabine. A total of 248 cycles were administered (median per patient 4, range 1-12). Treatment was stopped in 42 patients (74%) due disease progression (40 patients) or unacceptable toxicity (2 patients). Grade 3-4 toxicities occurred in 21 patients (38%) and consisted mainly of haematological adverse effects (neutropenia: 12.5%; thrombocytopenia: 6.5%; anaemia: 3.5%, asthenia: 9%, neurotoxicity: 12.5%). No toxic deaths occurred. Thirty-eight patients (67%) had a transient or permanent dose reduction (gemcitabine 49%, nab-paclitaxel 64%) because of asthenia (32%), haematological toxicities (45%) or peripheral neurotoxicity (29%). Seven patients (12.5%) had to stop Nab-paclitaxel permanently because of peripheral neurotoxicity [4] , hematological toxicity [2] or asthenia [1] . As regard efficacy, a clinical response was observed in 19 patients (33%), clinical stability in 21 patients (37%) and clinical progression in 17 patients (30%). Nab-paclitaxel plus gemcitabine resulted in an improvement in pain and asthenia in 63% of patients.
After a median follow-up of 17.5 months (range 5-45) since the beginning of FOLFIRINOX and 6 months (range 0.7-16 months) since the beginning of Nab-paclitaxel plus gemcitabine, median OS was 8.8 months (95% CI: 6.2-9.7). The OS rates at 6 and 12 months were, respectively, 69% (95% CI: 0.53-0.80) and 15% (95% CI: 0.03-0.36). Median PFS was 5.1 months (95% CI: 3.2-6.2). The PFS rates at 6 and 12 months were, respectively, 39% (95% CI: 0.25-0.52) and 6% (95% CI: 0.01-0.23). Median OS and PFS since the beginning of firstline chemotherapy (FOLFIRINOX) was 18 months (95% CI: 16-21.2) and 14 (95% CI: 12.8-15.4) months respectively.
Similarly, Caparello et al. conducted a prospective evaluation of 71 patients who underwent second line chemotherapy after modified FOLFIRINOX [28] . Likewise to the report by the French colleagues, 66% of the progressed patients were able to start a second-line treatment, with a combination regimen in 52% of the cases. Unfortunately, second-line treatment did not provide such encouraging results, achieving a median PFS of only 2.5 months, a median OS of 6.2 months and even a lower disease control rate compared with the report published by Portal et al (34% vs 58%), after a median follow up of 20.1 months. Of note, baseline patient characteristics in the two series were similar, with the sole exception of PS, as we included only 2.8% of patients with ECOG PS 2. Also in 13 patients (18%) treated with gemcitabine plus nab-paclitaxel after FOLFIRINOX, results disappointed in terms of both activity (RR: 7%; DCR: 23%) and survival (median PFS: 1.95 months; median OS: 5.4 months).
Regarding our study, we retrospectively analysed data about a homogeneous group of 41 patients treated with FOLFIRINOX first line chemotherapy and all underwent to EC-GEMCAP second line treatment after FOLFIRINOX failure (27 (65.9%) patients) or stable disease (14 (34.1%) patients). After a median follow-up of 16.9 months (range 4.2-56.9 months) since diagnosis, median OS was 16.9 months (95% CI: 14.74-19.0) with a OS rates at 6, 12 and 24 months of 95.1%, 80.5% and 31.7%, respectively.
As regards second line therapy, after median follow-up of 8.9 months (range 0.6-48.5 months) median OS was 8.9 months (95% CI: 6.9-10.9). The OS rates at 6, 12 and 24 months were 61%, 80.5% and 31.7%, respectively. EC-GEMCAP median PFS was 4.1 months (95% CI: 3.1-5.1). The PFS rates at 6 and 12 months were, respectively, 41.5% and 19.5%.
Although these data are lower, the finally median OS was similar to that emerged in the Portal trials (8.9 months, 95% CI: 6.9-10.9, vs 8.8 months, 95% CI: 6.2-9.7, respectively). Also DCR was similar in both studies (62.3% vs 58%). Interesting, EC-GEMCAP was well tolerated, without dose reductions or delays. Grade 3-4 EC-GEMCAP hematologic and no-hematologic toxicities were 39% (leucocytopenia 24.4%, thrombocytopenia 14.6%) and 12.2% (fatigue 2.4%, vomiting 7.3%, diarrhoea 2.4%), respectively (Table 2) , which has definitely helped to maintain a discreet ECOG PS during all treatment, avoiding the deterioration of the general conditions that often lead to early discontinuation of therapy and bad prognosis.
Finally, anecdotal, the case of a patient with locally advanced disease underwent to radically surgery after 6 cycles of EC-GEMCAP therapy. The patients are still alive from the diagnosis of April 2012, with a OS of 51 months. Intra-arterial therapy could in fact contribute to a better cytoreductive effect for the purposes surgery, without giving sequelae of peritumoral tissues, as often happens after radiation therapy.
Of course, our trial has several limitations as the retrospective nature, the number of sample, the lack of a randomization design and quality of life evaluation, but showed than EC-GEMCAP may be a viable second line therapeutic alternative after FOLFIRINOX, also in patients without optimal general conditions.
